Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

Reach

时间窗: Quarterly ; Months 1 to 46

The proportion of program patients with OUD and receiving MOUD (buprenorphine, naltrexone) within the index quarter.

Adoption

时间窗: Quarterly ; Months 1 to 46

The number of integrated prescribers of buprenorphine and/or naltrexone, who are actively prescribing MOUD.

Effectiveness

时间窗: Quarterly ; Months 1 to 46

Access: The proportion of patients prescribed MOUD who start the medication within 72 hours of diagnosis. For patients requiring detoxification for naltrexone, Access will be operationalized as the proportion of patients who start the medication within 72 hours of when it is safe or indicated by a physician. Retention: The proportion of patients who are retained in continuous care for at least 6-months from the start of medication, or if in time limited care situations (e.g., residential detoxification) for the entire treatment episode.

Implementation - Integrating Medications for Addiction Treatment (IMAT) Index

时间窗: Months 1,7,14,24,34,46

The IMAT integrates MOUD guidelines, expert consensus recommendations, the OUD care cascade, and best practice information into a team-assessment benchmark measure of current and future state MOUD capability and practice. The IMAT is composed of 45 items, rated on a 1 to 5 scale from: 1- Not Integrated, to 3- Partially integrated, to 5- Fully integrated. Intermediate ratings of 2 and 4, are ratings not at either a 3 or 5 level respectively. The benchmark items address policy, practice and workforce factors, and are clustered into seven dimensions of: 1) Infrastructure; 2) Clinic culture and environment; 3) Patient identification and initiating care; 4) Care delivery and treatment response monitoring; 5) Care coordination; 6) Workforce; and, 7) Staff training and development. The IMAT Total Score is a composite rating from 1 to 5 of overall MOUD care quality. It takes between 1 to 2 hours to complete.